NVS: Double Bottom detected on 5 Nov 2026

All prices, scores, and news on this page reflect data available before market open on .

Free example: 1 of 45 setups from the 5 Nov 2026 scan. Subscribers get the full list every trading day by 6 AM ET.

On 5 Nov 2026, our scan flagged NVS as a double bottom setup scoring 74 out of 98 (Good tier), with a 67% win probability based on our historical pattern database and a 0.92 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $164.98, the conservative target is $172.80 with a stop at $156.45.

74 of 98
Good
67%
Moderate
0.92 : 1
$7.82 to target $8.53 to stop
Swing Trading Plan
Entry
$164.98
$172.80
$156.45
2-7 trading days
Exp. Reward
+$4.10
Exp. Risk
-$1.49

Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.

Current Setup
NVS is forming a double-bottom pattern at $149.17 support with a current price of $164.98, sitting just 0.25% below its 52-week high. The pattern quality scores are moderate: structure 12.19/15, volume 12.0/12, and breakout 10.83/13, yielding an overall score of 74.02/98 with a 66.79% win probability. Key resistance sits at $164.48; a breakout would target $172.80 conservatively. RSI at 70.5 signals overbought conditions, though positive momentum is evident: +5.7% gain last week, +17.18% over one month. Volume is below average (0.85 ratio), which tempers conviction slightly.
Stock Context
Novartis raised full-year 2026 core operating income guidance on October 27, 2026, upgrading from a prior low single-digit decline outlook to in-line to low single-digit growth. Q3 2026 showed net sales growth of 4% to $14.5 billion and core operating income up 10% to $6 billion. Rhapsido peak sales guidance was increased to over $4 billion in combined indications. However, context is clouded by pipeline setbacks: the del-desiran trial failed on September 8, 2026, causing shares to fall 10%, and Novartis has missed two of three key pipeline tests this year after pelacarsen and del-desiran failed late-stage trials. Remibrutinib in multiple sclerosis provides a major remaining pipeline catalyst, with more data expected later in 2026. The stock has recovered from September lows, supported by operational upside and cost discipline.
What to Expect
A successful double-bottom breakout above $164.48 resistance would target $172.80 (9.5% upside from current price), measured conservatively. Volume confirmation is needed—current volume at 0.85x average provides limited confirmation; breakouts with relative volume above 1.2x have higher probability of sustained moves. The win probability of 66.79% is respectable but not exceptional given overbought RSI (70.5) and below-average volume ratio. Invalidation occurs below $149.17 support, which marked both bottom levels; closure there would negate the setup and suggest pattern failure.
Risk Factors
Multiple headwinds complicate the setup. Two major pipeline failures now threaten Novartis' growth plans after missing two of three key pipeline tests, reducing conviction on long-term thesis. RSI at 70.5 indicates overbought conditions, increasing pullback risk—stocks at extreme RSI often retrace 3-5% before resuming. Volume is structurally weak at 0.85x average, suggesting limited institutional support for a sustained breakout. The stock trades at 31.39x PE (TTM), reflecting high valuation; any negative catalyst could pressure multiples. LOU064 data is due November 6, 2026, representing near-term binary risk. Beta of 0.82 provides defensive characteristics but limits upside participation.
How We Find and Score This Setup
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading. What the terms mean →
Frequently Asked Questions
Is NVS a good swing trade?
NVS scored 74 out of 98 on our double bottom scan, with a 67% historical win probability over a 2-7 trading days hold. Good setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $164.98, with a conservative target of $172.80 and a stop loss at $156.45.
What would invalidate this double bottom setup?
A close below the stop loss at $156.45 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical double bottom setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.
Market & Sector Regime
Market
Bullish 0.96
-1.0 0 +1.0
Health Care Sector
Bullish 0.83
-1.0 0 +1.0
Other Patterns Detected Today
Flat Base
70 days in pattern
Strong 37.8
Ascending Triangle
45 days in pattern
Good 30.7
Overall Score
35 of 40
Strong
Pattern Quality
16 of 20
Strong
Setup
13 of 20
Moderate
R/R
10 of 18
Fair
Context
Pattern Quality Score
12 of 15
Strong
Structure
11 of 13
Strong
Breakout
12 of 12
Exceptional
Volume
Recent Performance
+5.7%
1W
+7.2%
2W
+17.2%
1M
+7.0%
3M
Momentum & Trend
RSI (14)
70.5
Overbought
MACD Histogram
+1.06
Strong Bullish
Bollinger Band Position
94.4%
Upper Band
Volatility & Risk
20-Day Volatility
0.28
Moderate
ATR %
2.1%
Medium
Beta
0.82
Market
Volume Analysis
Volume Ratio
0.85x
Average
20-Day Avg Vol
2.1M
shares / day
Current Volume
1.7M
shares traded
Price Levels
Target
$172.80
52W High
$165.39
Current
$164.98
Resistance
$164.48
Stop Loss
$156.45
Support
$149.17
52W Low
$119.58
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.